Sun Pharma Advanced Research Company Limited

Equities

SPARC

INE232I01014

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:49 2024-04-19 am EDT 5-day change 1st Jan Change
332.6 INR -5.00% Intraday chart for Sun Pharma Advanced Research Company Limited -18.54% +15.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Sun Pharma Advanced Research Company Limited - Special Call
Sun Pharma Advanced Research Company Limited Announces Results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson's Disease CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Sun Pharma Advanced Research Company Limited - Special Call
Transcript : Sun Pharma Advanced Research Company Limited - Special Call
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sun Pharma Advanced Research Company Limited Announces Retirement of Chitturi Trinadha Rao as Senior Vice President, Drug Discovery CI
Sun Pharma Advanced Research Company Ltd. Completes Enrolment in Proosek, A Global Phase 2 Study of Vodobatinib in Early Parkinson's Disease CI
Sun Pharma Advanced Research Company Limited Announces Incorporation of Wholly Owned Subsidiary Company CI
Sun Pharma Advanced Research Company Limited Appoints Kajal Damania as Company Secretary CI
Sun Pharma Advanced Research Company Limited Announces the Resignation of Mr. Dinesh Lahoti as Company Secretary and Compliance Officer CI
Sun Pharma Advanced Research Company Limited Announces Resignation of Dinesh Lahoti as Company Secretary and Compliance Officer, Effective September 11, 2023 CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sun Pharma Advanced Research Company Limited Announces That FDA Issues Complete Response Letter for Pdp-716 Nda Due to Inspection Findings At Third-Party Api Manufacturing Facility CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Indian shares open higher as SVB acquisition hopes aid sentiment RE
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Sun Pharma Advanced's Partner Launches Neonatal Seizure Drug SEZABY in US MT
Sun Pharma Advanced, Sun Pharma Get US FDA Nod for Neonatal Seizures Treatment Drug MT
Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures CI
Sun Pharma Unit and SPARC Sign Licensing Deal for Neonatal Seizure Drug in US MT
Sun Pharma and Sun Pharma Advanced Research Company Ltd Sign Licensing Agreement CI
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Transcript : Sun Pharma Advanced Research Company Limited - Special Call
Sun Pharma Advanced Research Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Chart Sun Pharma Advanced Research Company Limited
More charts
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage bio-pharmaceutical company. The Company is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The Company develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. It has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. It has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. It has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.
More about the company
  1. Stock Market
  2. Equities
  3. SPARC Stock
  4. News Sun Pharma Advanced Research Company Limited
  5. Sun Pharma Advanced Research : Shareholders Approve Appointment of CEO